Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2019-07-01 Regulatory Filings
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure and Asieris enter into a global licensing deal for Cevira® with up to USD 250 million in milestones and double-digit royalties
Regulatory Filings Classification · 99% confidence The document is a press release dated July 1, 2019, announcing a 'global licensing deal' between Photocure and Asieris for the drug Cevira®. It details financial terms (signing fees, milestones up to USD 250 million, royalties) and strategic rationale. This type of announcement, detailing a major corporate transaction involving licensing rights and future revenue potential, fits best under the Capital/Financing Update category, as it directly impacts the company's financial structure and future earnings potential through a major deal. While it is an announcement, it is not announcing the publication of a standard periodic report (like 10-K or IR), making 'CAP' more specific than the general 'RPA' or 'RNS'.
2019-07-01 English
Photocure and Asieris enter into a global licensing deal for Cevira® with up to USD 250 million in milestones and double-digit royalties
Capital/Financing Update Classification · 95% confidence The document is a press release dated July 1, 2019, announcing a 'global licensing deal' between Photocure and Asieris for the drug Cevira®. It details financial terms (signing fees, milestones up to USD 250 million, royalties) and strategic rationale. This type of announcement, detailing a major corporate transaction involving licensing rights and future revenue potential, fits best under 'Capital/Financing Update' (CAP) as it directly relates to the monetization and structuring of company assets/products, or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure without a better fit. However, since it describes a significant financial agreement and partnership structure, CAP is the most appropriate specific category among the choices, as it covers financing activities and capital structure changes related to asset monetization. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a specific corporate action announcement, not a general regulatory filing (RNS) or a report publication announcement (RPA).
2019-07-01 English
Photocure ASA - Extraordinary general meeting held
AGM Information Classification · 98% confidence The document is explicitly titled 'PROTOKOLL FRA EKSTRAORDINÆR GENERALFORSAMLING' (Minutes from Extraordinary General Meeting) and contains detailed records of the proceedings, including the opening, election of the chairperson, approval of the agenda, and voting results for the election of board members. This content directly corresponds to the documentation generated following a shareholder meeting. Since it is the official minutes recording the decisions made, it falls under the category for AGM-related materials, specifically the minutes of the meeting itself, which aligns best with 'AGM Information' (AGM-R), as it documents the meeting's outcome and resolutions.
2019-06-19 Norwegian
Photocure ASA - Extraordinary general meeting held
AGM Information Classification · 98% confidence The document explicitly states it concerns an 'Extraordinary general meeting held' on June 19, 2019, and mentions the election of new board members. This directly relates to the proceedings and outcomes of a shareholder meeting. Although it mentions attached minutes, the primary subject is the meeting itself and its results (board election). This aligns best with the AGM Information category, which covers presentations and materials shared during General Meetings, even if it is an 'Extraordinary' one. The code AGM-R covers general meeting information.
2019-06-19 English
Photocure ASA: Mandatory notification of trade
Transaction in Own Shares Classification · 99% confidence The document is titled 'Photocure ASA: Mandatory notification of trade' and explicitly states that the company 'repurchased 1,694 own shares... in relation to the long-term incentive programme'. This action, the repurchase of own shares, directly corresponds to the definition of 'Transaction in Own Shares'. The document length is very short (796 chars), but the content is a direct announcement of the transaction itself, not just an announcement of a report, making POS the most specific fit over RNS or RPA. It is a report of the company buying back its own shares.
2019-06-18 English
HEXVIX® AT NUF 2019: FOCUS ON THE PATIENT EXPERIENCE
Regulatory Filings Classification · 95% confidence The document is titled with a specific event ('HEXVIX® AT NUF 2019') and details presentations and findings from a medical congress (Scandinavian Association of Urology). It includes quotes from the CEO, scientific findings, and background information on a medical product (Hexvix®). This structure strongly suggests a press release or news announcement summarizing recent corporate/product developments presented at an external event. Since it is not a formal regulatory filing (like 10-K, IR, or ER), nor a presentation deck (IP), the most appropriate classification is a general Regulatory Filing (RNS) which often serves as a catch-all for press releases that don't fit other specific categories like DIV or CAP. Given the content is a news announcement, RNS is the best fit among the provided options.
2019-06-11 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.